Therapeutic effect of pioglitazone combined different drugs on diabetic cardiopathy and its influence on cardiac function / 心血管康复医学杂志

ABSTRACT

Objective:To study therapeutic effect of pioglitazone hydrochloride combined different drugs on diabetic cardiopathy (DC) and its influence on cardiac function.Methods:A total of 118 DC patients were selected from our hospital.They were randomly and equally divided into group A (received pioglitazone hydrochloride + nifedipine sustained release tablet ) and group B (received pioglitazone hydrochloride + α-lipoic acid + mecobalamin ),both groups were treated for two months.Related indexes of blood glucose,vascular endothelial function,islet β cell function,heart ejection function before and after treatment,and incidence of adverse reactions were observed and compared between two groups.Results:Compared with before treatment,there were significant reductions in levels of fasting blood glucose (FBG),2h postprandial blood glucose (2hPG),glycosylated hemoglobin A1c (HbA1c),ho-meostasis model-insulin resistance index (HOMA-IR),high sensitive C reactive protein (hsCRP),vascular endothe-lial cell protein C receptor (EPCR),plamsa thrombin regulation protein (TM) and von Willebrand factor (vWF),and significant rise in insulin sensitivity index (ISI),left ventricular ejection fraction (LVEF),left ventricular frac-tional shortening (LVFS) and left ventricular early diastolic peak flow velocity/late diastolic peak flow velocity (E/A) in two groups after treatment,P＝0.001 all.There were no significant difference in above indexes after treat-ment between two groups,P＞0.05 all.No obvious adverse reactions were found in two groups during treatment.Conclusion:Both pioglitazone hydrochloride + nifedipine sustained release tablet and pioglitazone hydrochloride +α-lipoic acid + mecobalamin can significantly reduce blood glucose level,improve insulin resistance,vascular endo-thelial function and cardiac function with low incidence rate of adverse reactions in DC patients,which is worth clin-ical application.